Combining heat ablation, immunotherapy, and anti-angiogenic drugs for advanced cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether using microwave ablation (a heat treatment to destroy tumors) together with immunotherapy (drugs that help your immune system fight cancer) and possibly anti-angiogenic drugs (which block blood supply to tumors) can work better for advanced lung or liver cancer that has already been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer or liver cancer (hepatocellular carcinoma).
- You have already received at least one type of systemic treatment (like chemotherapy, targeted therapy, or immunotherapy).
- You are between 18 and 75 years old.
- You are able to take care of yourself most of the day (ECOG score 0, 1, or 2).
- Your blood counts, liver, and kidney function are within the required ranges (your doctor can check this).
- You do not have serious heart conditions, active autoimmune diseases (except well-managed thyroid or skin issues), or uncontrolled brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining microwave ablation (heat treatment of tumors) with two drugs—tislelizumab (an immune-boosting drug) and docetaxel (chemotherapy)—for patients with advanced non-small cell lung cancer whose disease progressed after initial immunotherapy. The goal is to see if this combination can slow or shrink tumors better than standard treatment alone.
This Phase 2 trial studies whether combining microwave ablation (a procedure to destroy lung tumors) with an immune checkpoint inhibitor can control multiple early lung cancers safely. It also aims to see how well the immune treatment helps after ablation, in people whose cancers have not spread.
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
This study tests a new treatment combining tumor destruction with heat/cold (ablation) and an immunotherapy drug (PD-1) for people whose pancreatic cancer has spread to the liver. The goal is to help the immune system fight the cancer better.
This trial tests a new combination treatment that uses heat (ablation) and other therapies to destroy liver tumors. It's for people who cannot have surgery or choose not to, and whose tumor is a specific size.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.